AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 6.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: MarketWatch · Stocktwits · Fierce Pharma · Yahoo Finance · Reuters · WSJ · CNBC · STAT.
How this dossier is built: methodology · AI policy · corrections.
Sources (8)
- Major drugmaker loses $27 billion in market value after failed trial MarketWatch · 46d ago
- BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal Stocktwits · 46d ago
- AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction Fierce Pharma · 46d ago
- IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 Years Yahoo Finance · 46d ago
- AstraZeneca's Wainua fails key heart disease trial, shares tumble Reuters · 46d ago
- AstraZeneca, Ionis Stocks Stumble After Heart Drug Fails Key Trial WSJ · 46d ago
- AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse CNBC · 46d ago
- AstraZeneca, Ionis report major trial failure with heart disease drug STAT · 46d ago
The story so far
AstraZeneca and Ionis have reported a major trial failure for their heart disease drug, Wainua. The news has led to a decline in share prices for both companies.
Coverage from Reuters, CNBC, and the Wall Street Journal emphasizes the market impact, noting that AstraZeneca stock dropped 9%. Yahoo Finance reports that Ionis (IONS) is heading toward its biggest single-day slump in over five years.
Further updates are expected as the companies address the trial miss, which CNBC described as a rare blow to the pharmaceutical powerhouse AstraZeneca.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46d ago.
The obvious questions
Which drug failed the clinical trial?
The heart disease drug named Wainua.
How did AstraZeneca's stock react?
According to CNBC, AstraZeneca stock dropped 9%.
What is the impact on Ionis stock?
Yahoo Finance reports that IONS stock is heading toward its biggest single-day slump in over five years.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K.
Eli Lilly's new weight-loss pill Foundayo is now available in the U.K., marking a significant milestone in the pharmaceutical industry.
Meet VO2 maxxing: The fitness ‘trend’ that could help you live longer
A new fitness trend promises longer life, but the science is not settled
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial
Positional isomerisation of pyridine via nitrogen transposition
Scientists have found a way to move a single nitrogen atom to create new drug candidates, challenging conventional chemistry.
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
5 Heart-Healthy Habits Doctors Wish More People Started Sooner
A cardiologist's 8,000 surgeries inform new advice on heart health habits
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.